(Q31082841)

English

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

phase III clinical trial

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Thomas Blevins

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Francesco Giorgino

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Ryan T Hietpas

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Fady T Botros

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

15 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

776-790

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Drug-induced hypoglycaemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Circulation and degradation of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Exenatide-associated ischemic renal failure.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide-induced acute kidney injury

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2810

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31082841&oldid=1976003727"